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Research
AbstrACt
Objective We have assessed HIV-1 disease progression 
among HIV-1-positive mothers in relation to duration of 
any or exclusive breast feeding in the context of ANRS 
12174 trial.
Methods The analysis was completed on 203, 212, 272 
and 529 HIV-1-positive and lactating mothers with CD4 
count >350 cells/µL from Burkina Faso, South Africa, 
Uganda and Zambia, respectively. The trial compared 
lamivudine and lopinavir/ritonavir as a peri-exposure 
prophylaxis during a 50-week follow-up time. A multiple 
logistic regression model was run with the mothers’ 
weight, CD4 count and HIV-1 viral load as separate 
dependent variables, then combined into a dependent 
composite endpoint called HIV-1 disease progression 
where HIV-1 viral load was replaced by the HIV-1 clinical 
stage. Exclusive or predominant breast feeding (EPBF) 
and any breastfeeding duration were the key explanatory 
variables.
results In the adjusted model, the associations 
between EPBF duration and weight change, CD4 
cell count and the HIV-1 viral load were consistently 
insignificant. The CD4 cell count was associated with 
a significantly higher mothers’ body mass index (BMI; 
a mean increase of 4.9 (95% CI 2.1 to 7.7) CD4 cells/
µL per each additional kilogram per square metre of 
BMI) and haemoglobin concentration (19.4 (95% CI 
11.4 to 27.4) CD4 cells/µL per each additional gram 
per decilitre of haemoglobin concentration). There was 
no significant association between EPBF duration and 
HIV-1 disease progression. A higher education level 
was a factor associated with a slower HIV-1 disease 
progression.
Conclusion Breast feeding was not a risk factor for a 
faster progression of HIV-1 disease in mothers of this 
cohort with a baseline CD4 cell count >350 cells/µL.
trial registration number NCT0064026; Post-results.
IntrOduCtIOn 
In 2015, 36.7 (34.0–39.8) million people were 
infected with HIV. Among them, 17.4 (16.1–
20.0) million were women of childbearing 
age.1 2 HIV-1 prevalence was estimated 
between 5.3% and 6.5% among pregnant 
women in sub-Saharan Africa.3 Because of 
the almost irreversible immune activation 
involved, HIV-1 infection creates a condition 
of metabolic stress that may result in wasting 
and immune depression.4–7 Ten per cent 
weight loss and a CD4 count of <350 cells/µL 
in the context of HIV-1 infection have been 
recognised as major criteria of the diagnosis 
of AIDS.8 This weight loss is also associated 
strengths and limitations of this study
 ► Our study has been implemented in four countries 
in Africa, namely Burkina Faso (West), South Africa 
and Zambia (South), and Uganda (East), which made 
our sample representative of the wider sub-Sahara 
African population.
 ► The data were collected in the context of a rigorous 
clinical trial, which minimised the loss to follow-up, 
the missing data as well as other data collection er-
rors, and therefore improved the quality of our data.
 ► However, the selection associated with the environ-
ment of a clinical trial, usually quite different from a 
routine environment, may have biased our findings.
 ► Nonetheless, the variables analysed separately as 
dependent variables or as part of our composite 
endpoints (mother’s weight, CD4 cell count, HIV-1 
viral load or HIV-1 clinical stage) were sufficiently 
robust and had a high validity.
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with a higher risk of mortality in HIV-1-infected breast-
feeding mothers.9 Furthermore, HIV-1 is a major cause 
of maternal mortality in affected countries in Southern 
Africa. About 25% of pregnancy-related deaths in sub-Sa-
haran Africa are attributable to HIV,10 and 88% of deaths 
among pregnant and postpartum women with HIV infec-
tion are attributable to the virus.11 
In women, pregnancy is, though a physiological condi-
tion, a period of increased metabolic activities and 
synthesis requiring a supplement of energy and nutri-
ents. After delivery, breast feeding prolongs the increased 
metabolic demands. Despite this, WHO still recommends 
HIV-1-infected women to breast feed as the best choice 
for the infant and the mother12 in contexts where replace-
ment feeding does not meet AFASS (affordable, feasible, 
available, safe and sustainable) criteria.
There have been conflicting results on assessment of 
the impact of breast feeding in HIV-1-infected mothers. 
Some studies found that breast feeding was harmful to 
HIV-positive mothers by either accelerating HIV disease 
progression as assessed by the mother’s weight loss, a 
decrease in CD4 cell count or even an increased risk 
of maternal mortality, suggesting that metabolic, immu-
nological or hormonal changes associated with breast 
feeding may accelerate HIV-1 disease progression in 
postpartum mothers.13–15 Others found no effect on 
the mothers’ health assessed by death, development 
of a low CD4 cell count, anaemia or excessive weight 
loss.16 17 Some studies have found breast feeding protec-
tive, allowing weight gain in HIV-1-infected breast-
feeding mothers.15 18–22
In the ANRS 12174 trial, we assessed mothers’ HIV-1 
disease progression (measured by the change in weight, 
CD4 cell count and HIV-1 disease stage as per WHO clas-
sification) in relation to exclusive breast feeding or dura-
tion of any breast feeding during the infant first 6 months 
of life and until week 50 post partum.
MethOds
study design
The ANRS 12174 clinical trial in Ouagadougou (Burkina 
Faso), East London (South Africa), Mbale (Uganda) and 
Lusaka (Zambia) was conducted from 2009 to 2013. The 
protocol and the main outcome have been published.23 24 
Briefly, a cohort of HIV-1-infected, pregnant women, at 
the time not eligible for highly active antiretroviral therapy 
because CD4 count was >350 cells/µL, aged 18 or 
above and planning to breast feed were identified from 
antenatal clinics between 28 and 40 weeks of amenor-
rhoea. As part of the HIV post-test counselling session, 
they were informed on the different feeding options for 
their babies. Only women intending to breast feed were 
referred to the research clinic for further assessment of 
the inclusion criteria during the antenatal period and 
again with their child within 6 days after birth, for an 
enrolment and randomisation at day 7 post partum. From 
28 weeks of pregnancy to day 7 after birth, programmatic 
mother-to-child transmission prophylaxis was imple-
mented with antepartum zidovudine, intrapartum single-
dose nevirapine and zidovudine–lamivudine for mothers 
and nevirapine for infants for 7 days postpartum. Twins 
and triplets, infants with positive HIV-1 DNA PCR test 
result at day 7 (±2 days) post partum, low birthweight or 
ill babies (ranked grade II or above of the ANRS classifi-
cation for adverse events) were excluded.25 The interven-
tion provided an infant prophylaxis in the breastfeeding 
period plus 1 week from day 7 to 50 weeks of age with 
either lopinavir/ritonavir or lamivudine.
data management and analysis
Data were collected on a paper case-report form or 
directly entered online using the Electronic Data capture 
system: OpenClinica (http://www. openclinica. com). 
Twenty-four-hour and 1-week breastfeeding recalls were 
collected during the enrolment visit at day 7±2 days after 
birth and the 13 monthly scheduled follow-up visits that 
started at week 2. During these visits, mothers were asked 
in particular if they gave their infants other foods/liquids 
as well as breast milk. Prelacteal feeding data—
defined as any food item except mothers’ milk given to 
infants before initial breast feeding—were also collected 
at the enrolment visit.
The mothers at each visit were categorised into the 
following groups: (1) exclusive breast feeding, EBF (only 
breast milk being given to the infant without any other 
food or liquid, except medically prescribed drugs or vita-
mins); (2) predominant breastfeeding, PBF (breast milk 
with some liquid-based food, such as juice, tea, sugar water 
and salt water, including glucose without any kind of 
formula, or animal milk); and (3) mixed feeding, MF 
(breast milk with other solid-based or liquid-based food, 
including other kinds of milk). We thereafter combined 
EBF and PBF into one group called ‘exclusive or predom-
inant breastfeeding’ (EPBF) as PBF presented few cases 
and was assessed as having much the same risk as EBF, at 
least with regard to postnatal HIV transmission.26
During the follow-up visits, the mothers underwent a 
clinical assessment, including weight measurement and 
HIV-1 infection staging at the first screening visit or 
screening one (between 28 and 40 weeks of gestation), 
day 7 post partum, weeks 26 and 50; CD4 cell count anal-
ysis at screening one, weeks 26 and 50; and HIV-1 viral 
load at screening one, day 7, weeks 6, 14, 26, 38 and 50. 
The dependent variables were mothers’ weight, CD4 cell 
count and HIV-1 viral load considered separately and 
measured at the same time points as per above. We gener-
ated a new variable called ‘weight loss’, which was calcu-
lated as the mothers’ weight at W26 (because of missing 
data, mothers’ weights were not available for week 50) 
minus the baseline weight at day 7 post partum, which was 
compared with the baseline weight to assess if the loss had 
reached 10%. Furthermore, we combined CD4 cell count, 
mothers’ weight loss and HIV-1 disease stage as per WHO 
classification to create the composite endpoint called 
‘HIV-1 disease progression’. HIV-1 disease progression was 
3Somé EN, et al. BMJ Open 2018;8:e019239. doi:10.1136/bmjopen-2017-019239
Open Access
accelerated when CD4 cell count decreased to <350 cells/
µL, or the HIV-1 infection was assessed by the trial physi-
cian at stage 3 or above, or the mothers lost >10% of their 
weight; otherwise, HIV-1 disease progression was deemed 
absent or slow. Our main independent variable was EPBF 
(until week 26 post partum) or any breastfeeding (until 
week 50 post partum) duration. The data were collected 
by trained physicians, pharmacists, biologists and coun-
sellors. Seca-brand scales and stadiometers were used to 
measure the mother’s height and weight. Weights were 
rounded to the nearest 10 g and the height to the nearest 
millimetre. Weight and height were measured twice 
based on the WHO guidelines (http://www. who. int/ 
childgrowth/ training/ en/).
We first ran linear mixed-effect models that considered 
separately the mothers’ weight, CD4 cell count and HIV-1 
viral load changes as dependent variables, and EPBF or 
any breast feeding as key independent variables. The loss 
to follow-up were censored in a survival analysis completed 
to build the EPBF and any breastfeeding variables.27 When 
the inter-country variability was not significant, a linear 
multivariate regression analysis was run. We ran a logistic 
regression regarding the composite endpoint. Adjust-
ment covariates included baseline variables measured at 
the screening one visit (body mass index (BMI), educa-
tion level, marital status, haemoglobin concentration) or 
on day 7 post partum (mode of delivery, breastfeeding 
initiation time, the baby’s gender and the trial arm). 
These multivariate analyses were run taking all partici-
pants together and also as two strata comprising South 
African mothers (stratum 1) and Burkina Faso, Uganda 
and Zambia together (stratum 2) because South Africa 
presented important socioeconomic, cultural and demo-
graphic differences compared with the other countries. 
For continuous variables, the mean values with 95% CI 
were estimated, and for categorical variables, percentages 
were used. Associations between variables were tested 
using the χ2 test for categorical variables. STATA/SE 
V.13.1 statistical software has been used for the analyses.
ethics
Prior to enrolment, the mothers signed a written informed 
consent and assent forms for themselves and their chil-
dren, respectively. The trial was conducted according to the 
sponsor (ANRS) ethic charter, Good Clinical Practices and 
the principles of the Helsinki declaration.
results
In the ANRS 12174 trial, 1273 mother–infant pairs were 
randomised and six were excluded due to protocol viola-
tions. Of the remaining 1267 participants, 204 were from 
Ouagadougou, 222 from East London, 278 from Mbale 
and 563 from Lusaka. In all, 42 were excluded from anal-
ysis due to lack of breastfeeding data after inclusion, 7 
due to inaccurate feeding duration data and 2 women had 
no data on weights. The analysis included 1216 subjects. 
The complete flow chart has been published elsewhere.27 
The mean baseline weight, the percentage of educated 
and employed women was highest, and the mean EPBF 
Table 1a Baseline characteristics collected at screening one or on day 7 post partum and breastfeeding duration data 
(continuous variables)
Burkina Faso South Africa Uganda Zambia All sites
n=203 n=212 n=272 n=529 n=1216
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Mean duration of 
zidovudineregimen 
post-delivery (days)*
6.6 (6.5 to 6.8) 7 (7.0 to 7.0) 6.8 (6.7 to 6.9) 7.0 (6.9 to 7.0) 6.9 (6.8 to 7.0)
Mean duration 
of lamivudine regimen 
post-delivery (days)*
6.6 (6.5 to 6.8) Data not available 6.7 (6.6 to 6.8) 7.0 (6.9 to 7.0) 6.8 (6.8 to 6.9)
Mean baseline CD4 
count×102 cells/µL
5.6 (5.4 to 5.8) 5.5 (5.3 to5.7) 5.6 (5.4 to 5.8) 6.0 (5.8 to 6.2) 5.8 (5.7 to 5.9)
Mean baseline viral 
load×103 copies/µL
23.0 (7.3 to 38.7) 13.5 (7.5 to 19.6) 34.9 (19.7 to 50.0) 29.1 (21.5 to 36.6) 26.4 (21.1 to 31.8)
Baseline mothers’ 
weight (kg)
62.9 (61.4 to 64.5) 72.1 (70.0 to 74.1) 58.1 (57.0 to 59.2) 62.0 (61.0 to 62.9) 63.0 (62.3 to 63.7)
Mean EPBF duration 
(months)
6.3 (6.2 to 6.4) 4.8 (4.7 to 4.9) 5.6 (5.5 to 5.7) 6.0 (5.9 to 6.1) 5.8 (5.7 to 5.9)
Mean breastfeeding 
duration (months)
10.5 (10.4 to 10.6) 6.7 (6.6 to 6.8) 8.4 (8.3 to 8.5) 8.4 (8.3 to 8.5) 8.4 (8.3 to 8.5)
*AZT and 3TC (zidovudine and lamivudine) are usually administered together. However, in our data collection tool (the questionnaire), the 
investigators had to ask specifically and separately the question for AZT and 3TC. We suspect that they may have been some reporting 
errors, creating slight differences in the percentages of women who complied with the prophylaxis requirements.
EPBF, exclusive or predominant breast feeding.
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and any breastfeeding durations shortest in South Africa 
where the HIV-1 viral load was also the lowest (table 1a 
and b).
Overall, in the adjusted model, the association between 
EPBF duration and weight change was negative and 
non-significant. Mothers who completed secondary school 
had a significant mean increase of 1.1 kg compared with 
those who did not complete primary school (table 2a).
The association between CD4 cell count and EPBF 
duration was non-significant (5.4 (95% CI −0.1 to 10.9) 
and 4.5 (95% CI −6.2 to 15.1) CD4 cells/µL increase per 
month of EPBF duration at univariate and multivariate 
analyses, respectively). The association was significantly 
positive between the mothers’ baseline BMI, haemo-
globin concentration and CD4 cell count yielding a mean 
increase of 4.9 (95% CI 2.1 to 7.7) CD4 cells/µL per addi-
tional BMI unit and 19.4 (95% CI 11.4 to 27.4) CD4 cells/
µL per additional unit of haemoglobin throughout the 
EPBF period (table 2b).
There was no significant association between HIV-1 
viral load and EPBF duration. The heavier and older 
mothers, those who delivered female babies and the 
best educated women group had a significantly lower 
mean viral load in the multivariate analysis. The 
mothers allocated to the lopinavir/ritonavir group had 
a significantly higher mean viral load than the ones in 
the lamivudine arm (table 2c).
We found no significant association between EPBF 
duration and HIV-1 disease progression. However, 
randomisation to the lopinavir/ritonavir arm or being 
a single mother led to a significantly adjusted OR of 
1.3 (95% CI 1.0 to 1.6; P=0.04) and 1.6 (95% CI 1.3 to 
2.1), respectively (table 2d).
Considering any breastfeeding duration, there was no 
weight change at univariate and multivariate analyses 
overall (table 3a). Still regarding any breast feeding, overall, 
there was a significant mean increase of 5.7 (95% CI 0.4 to 
10.9) CD4 cells/µL per month of any breast feeding. We 
found also that being a single mother was associated with a 
mean decrease of −43.3 (95% CI −72.8 to −13.7) CD4 cells/
µL as compared with married ones (table 3b). Any breast-
feeding duration was also associated with a significantly 
higher mean viral load (table 3c). Analysis with any breast-
feeding pattern and HIV-1 disease progression showed the 
same associations as EPBF and HIV-1 disease progression 
(table 3d).
Table 1b Baseline characteristics collected at screening one or on day 7 post partum and breastfeeding duration data 
(categorical variables)
Burkina Faso South Africa Uganda Zambia All sites
n=203 n=212 n=272 n=529 n=1216
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Mother’s age group (years)
  Below 25 26.2 (20.5 to 32.6) 34.4 (28.3 to 41.1) 39.3 (33.7 to 45.3) 37.8 (33.8 to 42.0) 35.6 (33.0 to 38.3)
  25–30 36.9 (30.6 to 43.8) 31.2 (25.2 to 37.7) 35.7 (30.2 to 41.5) 33.1 (29.2 to 37.2) 34.0 (31.3 to 36.7)
  30 and above 36.9 (30.6 to 43.8) 34.4 (28.3 to 41.1) 25.0 (20.2 to 30.5) 29.1 (25.4 to 33.1) 30.4 (27.9 to 33.1)
HIV stage 1 93.1 (88.7 to 95.9) 98.6 (95.7 to 99.5) 92.3 (88.4 to 94.9) 99.8 (98.7 to 100.0) 96.8 (95.6 to 97.6)
Education
  Did not 
complete 
primary school
68.5 (61.7 to 74.5) 8.5 (5.4 to 13.1) 48.5 (42.6 to 54.5) 28.2 (24.5 to 32.2) 36.0 (33.4 to 0.38.8)
  Completed 
primary school
7.4 (4.5 to 11.9) 0.5 (0.1 to 3.3) 15.8 (11.9 to 20.6) 18.5 (15.4 to 22.1) 12.9 (11.1 to 14.9)
  Secondary 
school and 
more
24.1 (18.7 to 30.5) 91.0 (86.4 to 94.2) 35.7 (0.30.2 to 41.5) 53.3 (49.0 to 57.5) 51.1 (48.2 to 53.9)
Marital status 
(married)
90.6 (85.8 to 94.0) 39.1 (32.8 to 45.9) 82.0 (76.9 to 86.1) 88.7 (85.7 to 91.1) 78.9 (76.5 to 81.1)
Occupation 
(employed)
8.9 (5.6 to 13.6) 41.5 (35.0 to 48.3) 35.3 (29.8 to 41.2) 17.0 (14.0 to 20.5) 24.0 (21.7 to 26.5)
Primipara 21.7 (16.5 to 27.9) 33.5 (27.4 to 40.1) 18.0 (13.9 to 23.0) 20.6 (17.4 to 24.3) 22.4 (20.2 to 24.9)
Vaginal delivery 93.6 (89.3 to 96.2) 65.1 (58.4 to 71.2) 93.4 (89.7 to 95.8) 96.2 (94.2 to 97.5) 89.7 (87.9 to 91.3)
Breastfeeding 
initiation time 
(within 1 hour)
6.9 (4.1 to 11.3) 51.4 (44.7 to 58.1) 55.9 (49.9 to 61.7) 80.7 (77.1 to 83.9) 57.7 (54.9 to 60.5)
Lamivudine arm 49.7 (42.9 to 56.6) 51.9 (45.1 to 58.6) 49.6 (43.7 to 55.6) 50.3 (46.0 to 54.5) 50.3 (47.5 to 53.1)
Female baby 41.9 (35.2 to 48.8) 49.1 (42.4 to 55.8) 52.9 (46.0 to 58.8) 48.4 (44.1 to 52.7) 48.4 (45.6 to 51.2)
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In the stratified analysis, we found that EPBF duration had 
no influence on mothers’ weight, CD4 count or HIV-1 viral 
load, whatever the stratum. HIV-1 disease progression was 
not associated either with EPBF duration (table 2a, b, c and 
d). In stratum 2, C-section delivery was associated with an 
increase in CD4 cell count (table 2b), whereas delivering a 
female baby and being educated beyond secondary school 
were associated with a decrease in HIV-1 viral load (table 2c).
In South Africa, initiating breast feeding 1 hour 
post-delivery and being a single mother were related to 
an increase in HIV-1 viral load. In both strata, C-section 
delivery and multiparity were also related to an increase 
in HIV-1 viral load. There was no association between 
any breast feeding and the mothers’ weight, CD4 cell 
count and HIV-1 disease progression in any of the 
strata (table 3a, b and d). However, any breastfeeding 
duration was associated with an increase of the HIV-1 
viral load in South African women (table 3c).
dIsCussIOn
Considered separately, there appeared to be no variations 
in the mothers’ weight, CD4 cell count and HIV-1 viral 
Table 2a Mothers’ weight change according to EPBF duration adjusted to different covariates: stratification presenting South 
Africa versus the other sites and pooled analysis
South Africa
Burkina Faso, Uganda and 
Zambia Pooled analysis
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Dependent variable=mother’s weight
EPBF duration 
(months)
0.1
(−0.7 to 0.9)
−0.2
(−0.6 to 0.1)
−0.1
(−0.5 to 0.3)
0.1
(−0.0 to 0.3)
−0.2
(−0.5 to 0.2)
−0.1
(−0.2 to 0.1)
Baseline BMI
(kg/m2)
2.5
(2.4 to 2.7)
2.4
(2.3 to 2.6)
2.5
(2.4 to 2.6)
2.4
(2.3 to 2.5)
2.5
(2.4 to 2.6)
2.4
(2.3 to 2.5)
Mother’s age (years) 0.8
(0.5 to 1.2)
0.1
(0.0 to 0.3)
0.5
(0.4 to 0.6)
0.1
(0.1 to 0.2)
0.5
(0.4 to 0.7)
0.1
(0.1 to 0.2)
HIV disease stage
  HIV stage 1
  HIV stage >1 12.4
(−4.5 to 29.4)
6.7
(0.4 to 13.1)
−2.8
(−6.4 to 0.8)
Education
  Did not complete 
primary school
1 1 1 1
  Completed 
primary school
3.9
(2.0 to 5.9)
0.2
(−0.7 to 1.1)
4.4
(2.2 to 6.5)
0.6
(−0.3 to 1.5)
  Secondary school 
and more
2.7
(1.2 to 4.1)
0.7
(0.1 to 1.4)
3.1
(1.5 to 4.6)
1.1
(0.4 to 1.8)
Marital status
Married/
cohabiting mothers
1 1
  Single mothers −3.1
(−7.2 to 0.9)
−1.2
(−3.0 to 0.5)
Delivery
  Vaginal delivery 1 1 1 1
  C-section delivery 3.7
(−0.4 to 7.9)
4.5
(1.5 to 7.6)
4.4
(2.1 to 6.7)
−1.1
(−2.1 to −0.1)
Parity
  Primipara 1 1 1 −
  Multipara 6.1
(1.9 to 10.3)
3.1
(1.4 to 4.7)
3.9
(2.3 to 5.4)
−
Trial arm
  Lamivudine arm 1 1 1 1 1 1
Lopinavir/
ritonavir arm
2.0
(−2.0 to 6.1)
0.8
(−0.7 to 2.3)
−0.1
(−1.4 to 1.3)
−0.3
(−0.9 to 0.2)
0.3
(−1.0 to 1.6)
−0.1
(−0.7 to 0.4)
BMI, body mass index; EPBF, exclusive or predominant breast feeding.
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load related to EPBF or any breast feeding. The same 
conclusion applied to these outcomes was combined in a 
composite endpoint representing HIV-1 disease progres-
sion. Unsurprisingly, mothers’ baseline BMIs were consis-
tently associated with an increase in the mothers’ weight 
and CD4 cell count, and with a lower mean HIV-1 viral 
load for both EPBF and any breastfeeding groups.
In a review of the literature on weight change in the 
postpartum period, there appeared to be no association 
between breast feeding or generally between the mode 
Table 2b Mothers’ CD4 cell count change according to EPBF duration adjusted to different covariates: stratification 
presenting South Africa versus the other sites and pooled analysis
South Africa Burkina Faso, Uganda and Zambia Pooled analysis
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Dependent variable=CD4 cell count
EPBF duration (months) −1.0
(−8.9 to 7.0)
−6.4
(−18.6 to 5.8)
9.3
(2.3 to 16.3)
7.9
(−4.2 to 20.1)
5.4
(−0.1 to 10.9)
4.5
(−6.2 to 15.1)
Baseline BMI (kg/m2) 4.9
(2.4 to 7.3)
5.9
(2.5 to 9.2)
3.3
(1.3 to 5.3)
4.9
(2.1 to 7.7)
Mother’s age (years) −3.1
(−7.5 to 1.2)
−4.9
(−7.3 to −2.5)
−6.2
(−8.6 to −3.8)
−4.7
(−6.9 to −2.6)
−6.2
(−8.4 to −4.1)
Haemoglobin 
concentration (g/dL)
33.3
(12.7 to 53.8)
34.8
(14.4 to 55.1)
15.2
(7.8 to 22.6)
12.9
(4.6 to 21.2)
19.3
(12.3 to 26.4)
19.4
(11.4 to 27.4)
Breastfeeding initiation 
time
  Breastfeeding 
initiation within 1 hour
1 1 1 1 1 −
  Breastfeeding 
initiation after 1 hour
−56.2
(−94.9 to −17.4)
−39.9
(−90.3 to 10.6)
−40.5
(−60.1 to −20.9)
−42.5
(−61.1 to −23.9)
−
Child’s gender
  Male babies 1 1 1
  Female babies −53.1
(−104.7 to −1.6)
−52.9
(−103.0 to −2.9)
21.8
(−3.9 to 47.4)
HIV disease stage
  HIV stage 1 1 1 1 1
  HIV stage >1 −85.8
(−131.5 to −40.2)
−86.5
(−147.1 to −26.0)
−70.2
(−115.5 to −25.0)
−83.7
(−144.1 to −23.4)
Education
  Did not complete 
primary school
1 1 1
  Completed primary 
school
29.2
(−8.6 to 67.1)
25.1
(−12.6 to 62.9)
24.4
(−12.9 to 61.6)
  Secondary school 
and more
1.0
(−26.8 to 28.9)
−7.8
(−34.9 to 19.3)
−9.3
(−36.8 to 18.2)
Marital status
  Married/cohabiting 
mothers
1 1 1 1
  Single mothers −34.5
(−73.2 to 4.2)
−44.6
(−83.1 to −6.03)
−24.6
(−55.9 to 6.6)
−29.7
(−61.0 to 1.6)
Delivery
  Vaginal delivery 1 1
  C-section delivery 71.6
(11.7 to 131.4)
71.1
(11.1 to 131.2)
Trial arm
  Lamivudine arm 1 1 1 1 1 1
  Lopinavir/ritonavir 
arm
−33.4
(−69.2 to 2.3)
−65.3
(−116.4 to −14.1)
−12.8
(−31.6 to 6.1)
−12.9
(−38.2 to 12.4)
−15.8
(−32.6 to 1.0)
−19.2
(−41.9 to 3.6)
BMI, body mass index; EPBF, exclusive or predominant breast feeding.
7Somé EN, et al. BMJ Open 2018;8:e019239. doi:10.1136/bmjopen-2017-019239
Open Access
of infant feeding, and postpartum weight loss. However, 
C-section delivery was a risk factor for postpartum weight 
loss,28 similar to our findings. South Africa had mark-
edly lower rates of vaginal deliveries versus other coun-
tries (table 1b). In the year 2000, studies were published 
demonstrating that elective C-section before the labour 
and before the rupture of membranes added protection 
against HIV transmission to the newborn.29 30 The lower 
rates of vaginal deliveries in South Africa were likely 
due to the country policies (influenced by the scientific 
Table 2c Mothers’ HIV-1 viral load change according to EPBF duration adjusted to different covariates: stratification 
presenting South Africa versus the other sites and pooled analysis
South Africa Burkina Faso, Uganda and Zambia Pooled analysis
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Dependent variable=viral load (coefficient×103)
EPBF duration (months) 4.5
(−3.4 to 12.4)
−3.6
(−11.5 to 4.4)
5.4
(−7.1 18.0)
2.0
(−11.3 15.4)
6.2
(−2.5 to 14.9)
1.7
(−7.3 to 10.8)
Baseline BMI (kg/m2) −7.7
(−10.9 to −4.6)
−14.5
(−17.9 to −11.0)
−4.7
(−8.5 to −1.0)
−5.7
(−9.8 to −1.6)
−6.5
(−9.2 to −3.8)
−8.0
(−11.0 to −4.9)
Mother’s age (years) −2.7
(−5.3 to −0.1)
−2.7
(−5.5 to 0.1)
−1.9
(−4.6 to 0.8)
−4.5
(−7.7 to −1.4)
−2.1
(−4.3 to 0.1)
−4.5
(−7.0 to −2.0)
Breastfeeding initiation 
time
  Breastfeeding 
initiation <1 hour
1 1
  Breastfeeding 
initiation >1 hour
70.5
(41.3 to 99.7)
45.1
(13.5 to 76.7)
Child’s gender
  Male babies 1 1 1 1 1 1
  Female babies −49.1
(−79.4 to 18.7)
−19.5
(−48.5 to 9.4)
−36.5
(−66.0 to 7.2)
−25.3
(−49.2 to −1.4)
−35.2
(−59.2 to −11.1)
Education
  Did not complete 
primary school
1 1 1 1
  Completed primary 
school
−10.2
(−53.9 to 33.5)
2.9
(−41.4 to 47.2)
−5.0
(−45.1 to 35.2)
13.4
(−26.9 to 53.8)
  Secondary school 
and more
−76.7
(−108.1 to −45.3)
−73.4
(−105.9 to −41.0)
−72.7
(−98.7 to −46.7)
−62.0
(−89.7 to −34.3)
Marital status
  Married/cohabiting 
mothers
1 1
  Single mothers 55.6
(21.6 to 89.5)
127.9
(92.8 163.0)
Delivery
  Vaginal delivery 1 1 1 1 1 1
  C-section delivery 118.5
(86.4 to 150.5)
143.2
(108.8 to 177.5)
72.6
(6.8 to 138.4)
84.2
(17.6 to150.7)
90.8
(49.8 to 131.8)
105.5
(65.2 to 145.7)
Parity
  Primipara 1 1 1 1 1 1
  Multipara 66.5
(34.8 to 98.2)
125.9
(90.5 to 161.2)
47.7
(12.1 to 83.2)
56.7
(15.1 to 98.2)
54.8
(26.7 to 83.0)
65.1
(32.8 to 97.4)
Trial arm
  Lamivudine arm 1 1 1 1 1 1
  Lopinavir/ritonavir 
arm
−48.4
(−77.6 to −19.2)
−37.6
(−67.5 to −7.6)
39.9
(12.4 to 67.4)
47.0
(17.9 to 76.1)
22.6
(−0.0 to 45.2)
31.1
(7.1 to 55.0)
Birth weight (g) 0.0
(0.0 to 0.1)
0.1
(0.0 to 0.1)
0.0
(0.0 to 0.1)
0.1
(0.0 to 0.1)
BMI, body mass index; EPBF, exclusive or predominant breast feeding.
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evidence) that supported HIV-infected women towards 
delivering HIV-free babies. This support included free 
formulas and probably scheduled C-section for the HIV-in-
fected pregnant women and mothers. Why the rest of the 
countries did not implement the same policy is certainly 
a matter of affordability and availability of local resources. 
Another reason is that C-section rate is ‘recklessly high’ in 
South Africa where up to 90% of pregnant women deliver 
through this method in private hospitals (The Guardian, 
https://www. theguardian. com/ world/ 2014/ sep/ 24/ 
caesarean- section- south- africa (accessed on 27 October 
2017)). This practice may have spilled over but at a lesser 
extent into public health facilities. We believe this prac-
tice has not skewed our results since these C-section deliv-
eries were not medically indicated at first hand, at least 
not based on a vaginal delivery risk; therefore, they are 
not done on women with poorer health status. Actually, 
South African women had the lowest mean HIV-1 viral 
load and the highest mean BMI.
Yet, this review of literature28 found that less educated 
mothers (<12 years of schooling) were at risk of post-
partum weight retention; we found that higher educated 
women (secondary school or further) were at risk of that 
weight retention. This difference in our finding may be 
explained by the difference in our categorisation of the 
education variable. In our study, less educated partici-
pants included only women with primary school level, 
meaning around 6 years of schooling. Therefore, the 
results of the two studies are not really comparable. A 
higher education level was also a factor associated with a 
slower HIV-1 disease progression. This finding is consis-
tent with our result that higher educated women retained 
more weight.
In a further review of literature on the effects of lacta-
tion on the mother’s body weight, it is clear that the 
assumption that the postpartum weight loss is due to the 
high energy demand associated with lactation has been 
challenged by many studies.31 Some reports conflict with 
our own findings, such as the one in KwaZulu Natal, 
where HIV-1-infected mothers at between 8 and 24 weeks 
had a mean weight loss of 1.4 kg in contrast to a 0.4 kg 
weight gain in HIV-1-uninfected mothers (P=0.01) during 
breast feeding.15
Regarding the change in CD4 cell count, the South 
African data support the conclusion that CD4 cell count 
did not differ significantly between women who breast 
fed and those who did not.32 This finding contradicts the 
Kenyan study that found that the rate of CD4 cell count 
decline was higher in breastfeeding than in non-breast-
feeding mothers.13 However, in that Kenyan study, HIV-1 
RNA levels did not differ significantly between breast-
feeding and formula-feeding mothers.
Regarding HIV-1 disease progression, the same 
data showed no deleterious effect of breast feeding in 
HIV-1-infected mothers, similar to our study findings. 
The outcome variables were the CD4 and CD8 cell count, 
the mothers’ illness and mortality, and their haemo-
globin levels.32 Another study from Malawi reached the 
Table 2d Mothers’ HIV-1 disease progression according to EPBF duration adjusted to different covariates: stratification 
presenting South Africa versus the other sites and pooled analysis
South Africa
Burkina Faso, Uganda and 
Zambia Pooled analysis
Unadjusted 
OR
(95% CI)
Adjusted 
OR
(95% CI)
Unadjusted 
OR (95% CI)
Adjusted OR
(95% CI)
Unadjusted 
OR
(95% CI)
Adjusted OR 
(95% CI)
EPBF duration (months) 1.0 (0.9 to 1.1) 1.1 (1.0 1.2) 1.0 (0.9 to1.1) 1.1 (1.0 to 1.1) 1.1 (1.0 to 1.2)
Mother’s age (years) 1.0 (1.0 to 1.1) 1.0 (1.0 to 1.1) 1.0 (1.0 to 1.0)
Child’s gender
  Male babies 1 1 1
  Female babies 0.8 (0.6 to 1.0) 0.8 (0.6 to 1.0) 0.8 (0.6 to 1.0)
HIV disease stage
  HIV stage 1 1 1
  HIV stage >1 4.0 (2.5 to 6.2) 4.2 (2.6 to 6.5)
Marital status
  Married/cohabiting 
mothers
1 1 1 1
  Single mothers 1.6 (1.1 to 2.2) 1.8 (1.3 to 2.6) 1.5 (1.2 to 1.9) 1.6 (1.3 to 2.1)
Trial arm
  Lamivudine arm 1 1 1 1
  Lopinavir/ritonavir arm 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.7) 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.6)
Birth weight (g) 0.9 (0.8 to 1.0)
EPBF, exclusive or predominant breast feeding.
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same conclusion that breast feeding was not associated 
with higher risk of maternal morbidity or mortality.33 A 
study in Zambia concluded in the same direction that 
at 12 months after delivery, there was no difference in 
mortality between women who breast fed for a short dura-
tion (4 months) versus those who breast fed for a dura-
tion of their own choice.17 An individual patient data 
meta-analysis on mortality among HIV-1-infected mothers 
according to children’s feeding modality confirmed that 
the risk of dying within 18 months post partum was not 
significantly affected by the infants’ feeding modality (ie, 
ever vs never breast fed).34
In healthy breastfeeding mothers, the postpartum 
weight loss would be around 0.5 kg per month among 
population with relatively high mean of BMI. The 
mechanism of the weight loss would be burning of 
483–538 kcal per day.35 36 Therefore, losing weight after 
birth is likely when the mother’s calorie intake does not 
cover the calorie expense related to breast-milk produc-
tion. Considering these findings, we think that energy 
Table 3a Mothers’ weight change according to any breastfeeding duration adjusted to different covariates: stratification 
presenting South Africa versus the other sites and pooled analysis 
South Africa
Burkina Faso, Uganda and 
Zambia Pooled analysis
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
OR (95% CI)
Adjusted OR 
(95% CI)
Weight
Any breastfeeding duration 
(months)
0.3
(−0.2 to 0.8)
−0.1
(−0.3 to 0.0)
−0.0
(−0.3 to 0.2)
0.1
(0.0 to 0.3)
−0.0
(−0.3 to 0.2)
−0.0
(−0.2 to 0.1)
Baseline BMI (kg/m2) 2.5
(2.4 to 2.7)
2.5
(2.3 to 2.6)
2.5
(2.4 to 2.6)
2.4
(2.3 to 2.5)
2.5
(2.4 to 2.6)
2.4
(2.3 to 2.5)
Mothers’ age (years) 0.8
(0.5 to 1.2)
0.2
(0.0 to 0.3)
0.5
(0.4 to 0.6)
0.1
(0.1 to 0.2)
0.5
(0.4 0.7)
0.1
(0.1 to 0.2)
HIV disease stage
  HIV stage 1 1 1 1
  HIV stage >1 12.4
(−4.5 to 29.4)
6.4
(0.0 to 12.7)
−2.8
(−6.4 to 0.8)
Education
  Did not complete primary school 1 1 1 1
  Completed primary school 3.9
(2.0 to 5.9)
0.3
(−0.6 to 1.1)
4.4
(2.2 to 6.5)
0.6
(−0.3 to 1.5)
  Secondary school and further 2.7
(1.2 to 4.1)
0.9
(0.2 to 1.5)
3.1
(1.5 to 4.6)
1.0
(0.4 to 1.7)
Marital status
  Married/cohabiting mothers 1 1
  Single mothers −3.1
(−7.2 to 0.9)
−1.2
(−3.0 to 0.5)
Delivery
  Vaginal delivery 1 1
  C-section delivery 3.7
(−0.4 to 7.9)
−1.6
(−3.2 to 0.0)
4.5
(1.5 to 7.6)
4.4
(2.1 to 6.7)
−1.2
(−2.1 to −0.2)
Parity
  Primipara 1 1 1 1 1
  Multipara 6.1
(1.9 to 10.3)
3.1
(1.4 to 4.7)
3.9
(2.3 to 5.4)
Trial arm
  Lamivudine arm 1 1 1 1 1
  Lopinavir/ritonavir arm 2.0
(−2.0 to 6.1)
0.7
(−0.8 to 2.2)
−0.1
(−1.4 to 1.3)
−0.3
(−0.9 to 0.3)
0.3
(−1.0 to 1.6)
0.1
(−0.7 to 0.4)
BMI, body mass index.
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requirement and thus the metabolic stress related 
to breast feeding would be quite bearable. This may 
explain why in our study HIV-1-infected, immune-com-
petent and breastfeeding mothers’ health status was not 
deteriorated by breast feeding. This evidence inspires 
the idea that option A peri-exposure antiretroviral 
prophylaxis might still have pertinent indications since 
breast feeding remained the most frequent feeding 
Table 3b Mothers’ CD4 cell count change according to any breastfeeding duration adjusted to different covariates: 
stratification presenting South Africa versus the other sites and pooled analysis
South Africa Burkina Faso, Uganda and Zambia Pooled analysis
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted OR 
(95% CI)
Adjusted OR (95% 
CI)
CD4 cell count
Any breastfeeding duration 
(months)
0.4
(−6.8 to 7.6)
−2.4
(−9.5 to 4.7)
1.2
(−5.8 to 8.3)
9.8
(−2.1 to 21.8)
1.5
(−3.9 to 7.0)
5.7
(0.4 to 10.9)
Baseline BMI (kg/m2) 4.9
(2.4 to 7.3)
5.7
(2.4 to 9.1)
3.3
(1.3 to 5.3)
4.2
(1.5 to 6.9)
Mother’s age (years) −3.1
(−7.5 to 1.2)
−4.9
(−7.3 to −2.5)
−6.5
(−8.9 to −4.1)
−4.7
(−6.9 to −2.6)
−6.2
(−8.4 to −4.1)
Haemoglobin 
concentration (g/dL)
33.3
(12.7 to 53.8)
33.9
(13.5 to 54.3)
15.2
(7.8 to 22.6)
15.7
(7.2 to 24.3)
19.3
(12.3 to 26.4)
16.7
(9.0 to 24.4)
Breastfeeding initiation 
time
  Within 1 hour 1 1
  After 1 hour −56.2
(−94.9 to −17.4)
−40.5
(−60.1 to −20.9)
−42.5
(−61.1 to −23.9)
Child’s gender
  Male babies 1 1 1
  Female babies −53.1
(−104.7 to −1.6)
−54.1
(−104.3 to −3.6)
21.7
(−3.9 to 47.4)
HIV stage
  HIV stage 1 1 1 1 1
  HIV stage >1 −85.8
(−131.5 to −40.2)
−91.5
(−152.9 to −30.1)
−70.2
(−115.5 to −25.0)
−88.8
(−148.3 to −29.3)
Education
  Did not complete 
primary school
1 1 1
  Completed primary 
school
29.2
(−8.6 to 67.1)
25.1
(−12.6 to 62.9)
19.9
(−16.7 to 56.5)
  Secondary school and 
further
1.0
(−26.8 to 28.9)
−7.8
(−34.9 to 19.3)
−17.4
(−43.7 to 9.5)
Marital status
  Married/cohabiting 
mothers
1 1 1 1
  Single mothers −34.5
(−73.2 to 4.2)
−43.1
(−81.5 to −4.6)
−24.6
(−55.9 to 6.6)
−43.3
(−72.8 to −13.7)
Delivery
  Vaginal delivery 1 1
  C-section delivery 71.6
(11.7 to 131.4)
71.8
(11.9 to 131.7)
Parity
  Primipara 1
  Multipara
Trial arm
  Lamivudine arm 1 1 1 1 1 1
  Lopinavir/ritonavir arm −33.4
(−69 to 2.3)
−58.7
(−109.6 to −7.8)
−12.8
(−31.6 to 6.1)
−13.4
(−38.6 to 11.8)
−15.8
(−32.6 to 1.0)
−19.2
(−41.9 to 3.6)
BMI, body mass index.
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option in sub-Saharan Africa and since breast milk 
might still host HIV-1 reservoirs that mothers’ prophy-
laxis could not always 100% suppress.37
strengths and limitations
Our study has been implemented in four countries in Africa, 
including Burkina Faso (West), South Africa and Zambia 
(South) and Uganda (East). Therefore, we consider our 
study population representative of the sub-Sahara African 
population. The data were also collected in the rigorous 
context of a clinical trial, which minimised the loss to 
follow-up, the missing data as well as other data collection 
errors, and therefore improved the quality of our data.
However, the selection associated with the environment 
of a clinical trial—usually quite different from a routine 
environment—may have biased our findings. Nonethe-
less, our endpoints (mother’s weight, CD4 cell count and 
HIV-1 viral load) were sufficiently robust for us to vouch 
for their validity. Another point of note is the stratification 
of the participants into two strata, that is, South Africa 
versus Burkina Faso, Uganda and Zambia. This stratifica-
tion reduced the sample size in South Africa. Thus, some 
Table 3c Mothers’ HIV-1 viral load change according to any breastfeeding duration adjusted to different covariates: 
stratification presenting South Africa versus the other sites and pooled analysis
South Africa Burkina Faso, Uganda and Zambia Pooled analysis
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted 
coefficient
(95% CI)
Adjusted 
coefficient
(95% CI)
Unadjusted OR 
(95% CI)
Adjusted OR 
(95% CI)
HIV-1 viral load 
(coefficient×103) 
copies/µL
Any breastfeeding duration 
(months)
11.2
(6.8 to 15.6)
7.7
(3.4 to 12.1)
5.9
(−1.5 to 13.2)
2.5
(−5.2 to 10.2)
9.8
(4.9 to 14.7)
6.1
(1.0 to 11.2)
Baseline BMI (kg/m2) −7.7
(−10.9 to −4.6)
−14.0
(−17.4 to −10.6)
−4.7
(−8.5 to −1.0)
−5.7
(−9.8 to −1.5)
−6.5
(−9.2 to −3.8)
−7.6
(−10.7 to −4.5)
Mother’s age (years) −2.7
(−5.3 to −0.1)
−3.4
(−6.2 to −0.6)
−1.9
(−4.6 to 0.8)
−4.6
(−7.8 to −1.4)
−2.1
(−4.3 to 0.1)
−4.8
(−7.3 to −2.3)
Breastfeeding initiation time
  Within 1 hour 1 1
  After 1 hour 70.5
(41.3 to 99.7)
34.2
(2.7 to 65.7)
Child’s gender
  Male babies 1 1 1 1 1
  Female babies −49.1
(−79.4 to −18.7)
−19.5
(−48.5 to 9.4)
−37.2
(−66.6 to −7.9)
−25.3
(−49.2 to −1.4)
−36.2
(−60.2 to −12.2)
Education
  Did not complete primary 
school
1 1 1 1
  Completed primary school −10.2
(−53.9 to 33.5)
4.7
(−39.8 to 49.3)
−4.9
(−45.1 to 35.2)
16.6
(−23.8 to 57.0)
  Secondary school and further −76.7
(−108.1 to −45.3)
−70.7
(−104.4 to −37.1)
−72.7
(−98.7 to −46.7)
−54.5
(−82.8 to −26.1)
Marital status
  Married/cohabiting mothers 1 1 1
  Single mothers 55.6
(21.6 to 89.5)
124.9
(89.9 to 160.0)
Delivery
  Vaginal delivery 1 1 1 1 1 1
  C-section delivery 118.5
(86.4 to 150.5)
137.0
(102.7 to 171.2)
72.6
(6.8 to 138.4)
84.4
(18.0 to 150.7)
90.8
(49.8 to 131.8)
104.7
(64.5 to 144.9)
Parity
  Primipara 1 1 1 1 1 1
  Multipara 66.5
(34.8 to 98.3)
125.0
(89.8 to 160.3)
47.7
(12.1 to 83.2)
57.2
(15.6 to 98.8)
54.8
(26.7 to 83.0)
65.0
(32.7 to 97.3)
Trial arm
  Lamivudine arm 1 1 1 1 1 1
  Lopinavir/ritonavir arm −48.4
(−77.6 to −19.2)
−35.0
(−64.8 to −5.3)
39.9
(12.4 to 67.4)
47.6
(18.6 to 76.7)
22.6
(−60.2 to 45.2)
31.9
(8.0 to 55.8)
BMI, body mass index.
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of the modelling for South Africa could be less rigorous, 
and the findings regarding the risk factors there may not 
truly reflect the reality.
COnClusIOn
Breast feeding, whatever the type (exclusive or any) as 
far as this study can conclude, was not a risk factor for 
the HIV-1-infected mothers’ weight, CD4 cell count and 
HIV-1 viral load change, or HIV-1 disease progression, 
keeping in mind that all the participants had a baseline 
CD4 cell count >350 cells/µL. The mothers’ baseline 
high weight and high haemoglobin concentration were 
important factors in being consistently associated with an 
improvement of the outcome variables at stake. A higher 
education level was also a factor associated with a slower 
HIV-1 disease progression. Considering the benefits of 
breast milk for infants, and the consensus results from 
different studies elsewhere that breast feeding does not 
harm HIV-1-infected mothers, this study also supports the 
WHO 2016 guidelines on infant feeding, which indicate 
that mothers living with HIV should breast feed for at 
least 12 months and up to 24 months, provided that the 
right treatment or prophylaxis for the infection is given 
where formula feeding is unsafe.12
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